Equity Research firms currently have a positive stance on shares of Trillium Therapeutics Inc. (NASDAQ:TRIL). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.30. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $16.79 on a short term basis.
At the time of writing, the stock was trading at $16.69. This represents a change from the opening price of -0.06%. In terms of performance, year to date, the stock is 29.66%. The monthly stock performance comes in at 26.16%. For the quarter, shares are performing at 85.80%. Weekly performance analysis shows the equity at 12.45%.
In taking a look at technical levels, shares are trading 29.85% away from the 50 day simple moving average and 61.47% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -2.28% away from it’s 52- week high and 152.11% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Trillium Therapeutics Inc.’s RSI stands at 70.42. In looking at volatility levels, the shares saw weekly volatility of 7.48% and 7.80% over the past month.